Last reviewed 2026-05-29 · How we verify

1wIPV+2sIPV

Sinovac Biotech Co., Ltd · FDA-approved active Biologic ✓ Verified May 2026

1wIPV+2sIPV is a Inactivated polio vaccine (IPV) Biologic drug developed by Sinovac Biotech Co., Ltd. It is currently FDA-approved for Poliomyelitis prevention in infants and children.

This is an inactivated polio vaccine combining one dose of whole-virus IPV with two doses of split-virus IPV to provide immunization against poliovirus types 1, 2, and 3.

Researchers conducted a Phase IV clinical study (NCT07457060) to evaluate the immunogenicity and safety of a sequential vaccination of Sabin strain and wild strain inactivated poliovirus vaccine, specifically comparing the 1wIPV+2sIPV regimen. This study was conducted by Sinovac Biotech Co., Ltd. to assess the vaccine's effectiveness against poliomyelitis.

At a glance

Generic name	1wIPV+2sIPV
Sponsor	Sinovac Biotech Co., Ltd
Drug class	Inactivated polio vaccine (IPV)
Target	Poliovirus types 1, 2, and 3 antigens
Modality	Biologic
Therapeutic area	Immunology / Infectious Disease
Phase	FDA-approved

Mechanism of action

The vaccine works by introducing inactivated poliovirus antigens to stimulate humoral and cellular immune responses without causing disease. The combination of whole-virus and split-virus formulations is designed to optimize immunogenicity and safety profile. This heterologous prime-boost approach aims to enhance protective antibody responses against all three poliovirus serotypes.

Approved indications

Poliomyelitis prevention in infants and children

Common side effects

Local injection site reactions (pain, redness, swelling)
Fever
Irritability

Key clinical trials

Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

1wIPV+2sIPV CI brief — competitive landscape report
1wIPV+2sIPV updates RSS · CI watch RSS
Sinovac Biotech Co., Ltd portfolio CI

Frequently asked questions about 1wIPV+2sIPV

What is 1wIPV+2sIPV?

1wIPV+2sIPV is a Inactivated polio vaccine (IPV) drug developed by Sinovac Biotech Co., Ltd, indicated for Poliomyelitis prevention in infants and children.

How does 1wIPV+2sIPV work?

This is an inactivated polio vaccine combining one dose of whole-virus IPV with two doses of split-virus IPV to provide immunization against poliovirus types 1, 2, and 3.

What is 1wIPV+2sIPV used for?

1wIPV+2sIPV is indicated for Poliomyelitis prevention in infants and children.

Who makes 1wIPV+2sIPV?

1wIPV+2sIPV is developed and marketed by Sinovac Biotech Co., Ltd (see full Sinovac Biotech Co., Ltd pipeline at /company/sinovac-biotech-co-ltd).

What drug class is 1wIPV+2sIPV in?

1wIPV+2sIPV belongs to the Inactivated polio vaccine (IPV) class. See all Inactivated polio vaccine (IPV) drugs at /class/inactivated-polio-vaccine-ipv.

What development phase is 1wIPV+2sIPV in?

1wIPV+2sIPV is FDA-approved (marketed).

What are the side effects of 1wIPV+2sIPV?

Common side effects of 1wIPV+2sIPV include Local injection site reactions (pain, redness, swelling), Fever, Irritability.

What does 1wIPV+2sIPV target?

1wIPV+2sIPV targets Poliovirus types 1, 2, and 3 antigens and is a Inactivated polio vaccine (IPV).

Drug class: All Inactivated polio vaccine (IPV) drugs
Target: All drugs targeting Poliovirus types 1, 2, and 3 antigens
Manufacturer: Sinovac Biotech Co., Ltd — full pipeline
Therapeutic area: All drugs in Immunology / Infectious Disease
Indication: Drugs for Poliomyelitis prevention in infants and children

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing